Unresponsive Severe Aplastic Anemia in a Young Patient: Case Report and Short Review of the Literature

1. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: Diagnosis and classification. Autoimmun Rev. 2014;13:569-573.10.1016/j.autrev.2014.01.014Search in Google Scholar

2. Young NS. Acquired aplastic anemia. Ann Intern Med. 2020;136:534-546.10.7326/0003-4819-136-7-200204020-00011Search in Google Scholar

3. Savașan S. Acquired aplastic anemia: what have we learned and what is the horizon? Pediatr Clin North Am. 2018;65:597-606.Search in Google Scholar

4. Ahmed P, Chaudhry Q, Satti TM, et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology. 2020;25:48-54.10.1080/16078454.2019.1711344Search in Google Scholar

5. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509-2519.10.1182/blood-2006-03-010777Search in Google Scholar

6. Schoentler ML, Nathan DG. The pathophysiology of acquired aplastic anemia: current concepts revisited. Hematol Oncol Clin North Am. 2018;32:581-594.10.1016/j.hoc.2018.03.001Search in Google Scholar

7. Camitta BM. Criteria for severe aplastic anaemia. Lancet. 1988;1:303-304.10.1016/S0140-6736(88)90388-1Search in Google Scholar

8. DeZern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2012;4:221-230.Search in Google Scholar

9. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016:172:187-207.10.1111/bjh.1385326568159Search in Google Scholar

10. Scheinberg P. Recent advances and long-term results of medical treatment of acquired aplastic anemia: are pacients cured? Hematol Oncol Clin North Am. 2018;32:609-618.Search in Google Scholar

11. Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013;48:168-173.10.1038/bmt.2012.22023208312Search in Google Scholar

12. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Adv Hematol. 2012;120:1185-1196.10.1182/blood-2011-12-274019341871522517900Search in Google Scholar

13. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428-1436.10.1182/blood-2016-08-69348128096088Search in Google Scholar

14. Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643-1656.10.1056/NEJMra1413485Search in Google Scholar

15. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1973;45:355-363.10.1182/blood.V45.3.355.355Search in Google Scholar

16. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43-70.10.1111/j.1365-2141.2009.07842.xSearch in Google Scholar

17. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94:310-312.Search in Google Scholar

18. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56-68.10.1016/S0037-1963(00)90030-1Search in Google Scholar

19. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130-1135.10.1001/jama.289.9.113012622583Search in Google Scholar

20. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058-3065.10.1182/blood.V85.11.3058.bloodjournal85113058Search in Google Scholar

21. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191-2195.10.1182/blood.V93.7.2191Search in Google Scholar

22. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;11:622-627.10.1111/j.1365-2141.2006.06098.x16704436Search in Google Scholar

23. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11-19.10.1056/NEJMoa1200931342273722762314Search in Google Scholar

24. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818-1825.10.1182/blood-2013-10-534743396216124345753Search in Google Scholar

25. Winkler T, Cooper JN, Townsley DM, et al. Eltrombopag for refractory sever aplastic anemia: dosing, regiments, long-term follow-up, clonal evolution and somatic mutation profiling. Blood. 2017;130:777.10.1182/blood.V130.Suppl_1.777.777Search in Google Scholar

26. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540-1550.10.1056/NEJMoa1613878554829628423296Search in Google Scholar

27. Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Hematology Am Soc Hematol Educ Program. 2018;1:450-456.10.1182/asheducation-2018.1.450624597530504345Search in Google Scholar

28. Rodgers GM, Gilreath JA. Eltrombopag as initial monotherapy for severe aplastic anemia – a case report. Ann Hematol. 2018;97:1517-1518.10.1007/s00277-018-3303-z29560523Search in Google Scholar

29. National Library of Medicine (U.S.) (2014 March – 2020 December). hATG+CsA vs hATG+CsA+Eltrombopag for SAA (RACE). Identifier NCT02099747. https://www.clinicaltrials.gov/ct2/show/results/NCT02099747.Search in Google Scholar